Antares Pharma (ATRS) 10-Q2020 Q2 Quarterly report

Filed: 6 Aug 20, 4:38pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Austria, avoid, Canada, comply, comprised, Croatia, Denmark, directly, distancing, enacting, ensure, European, fact, featuring, Forsteo, governmental, home, Hungary, infection, Ireland, Israel, Kingdom, large, Portugal, reach, resumed, shifted, Sweden, treat, varying

Removed: incremental

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ATRS transcripts

ATRS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

ANTARES PHARMA, INC.

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

The undersigned, Robert F. Apple, the Chief Executive Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 (the “Report”).

The undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 6^th day of August, 2020.

/s/ Robert F. Apple

Robert F. Apple

President and Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.